2-(2-Piperazin-2-ylethoxy)ethanol | 509076-90-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(2-Piperazin-2-ylethoxy)ethanol
• CAS: 509076-90-8
• 化学式: C₈H₁₈N₂O₂
• 分子量: 174.24
• InChiKey: CDNGOUUFZNXQSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  53.5
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] DERIVES DE QUINAZOLINE POUR LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2004094410A1

  公开（公告）日：2004-11-04

  Quinazoline derivatives of formula (I); for use in the treatment of proliferative diseases such as cancer and in the preparation of medicaments for use in the treatment of proliferative diseases, and to processes for their preparation, as well as pharmaceutical compositions containing them as active ingredient.

  公式（I）的喹唑啉衍生物；用于治疗癌症等增殖性疾病，并用于制备用于治疗增殖性疾病的药物，以及它们的制备方法，以及含有它们作为活性成分的药物组合物。
• [EN] 4-(PYRAZOL-3-YLAMINO) PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DERIVES DE 4-(PYRAZOL-3-YLAMINO) PYRIMIDINE QUI S'UTILISENT DANS LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2005040159A1

  公开（公告）日：2005-05-06

  A compound of Formula (I); wherein the substituents are as defined in the text for use in modulating insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.

  一种化合物，其化学式为（I）；其中取代基如文本中定义的那样，用于调节类胰岛素生长因子1受体在温血动物（如人类）中的活性。
• [EN] SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)<br/>[FR] PYRIDONES SUBSTITUES INHIBITEURS DE LA POLY(ADP-RIBOSE) POLYMERASE (PARP)
  申请人：AVENTIS PHARMA INC

  公开号：WO2005097750A1

  公开（公告）日：2005-10-20

  The present invention discloses and claims a series of 2,3,5-substituted pyridone derivatives as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5'-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

  本发明公开并声明了一系列如下定义的2,3,5-取代吡啶酮衍生物。本发明还涉及制备这些化合物的方法。本发明的化合物是多聚腺苷酸二磷酸核糖酶（PARP）的抑制剂，因此在制药剂中特别用于治疗和/或预防各种疾病，包括与中枢神经系统和心血管疾病相关的疾病。
• [EN] INHIBITORS OF THE CHEMOKINE RECEPTOR CXCR3<br/>[FR] INHIBITEURS DU RÉCEPTEUR DE CHIMIOKINE CXCR3
  申请人：SANOFI AVENTIS

  公开号：WO2009105435A1

  公开（公告）日：2009-08-27

  This invention is directed to a 3-(amido or sulphamido)-4-(4-substituted-azinyl)benzamide or benzsulphonamide compound as defined herein. The 3-(amido or sulphamido)-(4-substituted-azinyl)benzamide or benzsulphonamide compound is useful as a inhibitor of the chemokine receptor CxCR3, and for preventing or treating a CxCR3 chemokine receptor mediated disease or condition related thereto in a patient in need of such.

  本发明涉及一种如下所定义的3-(酰胺或磺胺基)-4-(取代的4-吡啶基)苯甲酰胺或苯磺酰胺化合物。所述的3-(酰胺或磺胺基)-(取代的4-吡啶基)苯甲酰胺或苯磺酰胺化合物可用作趋化因子受体CxCR3的抑制剂，并用于预防或治疗患有CxCR3趋化因子受体介导的疾病或相关病况的患者。
• Aromatic sulfone hydroxamic acid metalloprotease inhibitor
  申请人：Barta E. Thomas

  公开号：US20060084688A1

  公开（公告）日：2006-04-20

  A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. The administered enzyme inhibitor corresponds in structure to formula (I), below, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are both hydrido or R 1 and R 2 together with the atoms to which they are bonded form a 5- to 8-membered ring containing one, two, or three heteroatoms in the ring that are oxygen, sulfur, or nitrogen. R 3 in formula (I) is an optionally substituted aryl or optionally substituted heteroaryl radical. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor.

  本发明揭示了一种治疗方法，包括向患有与病理性基质金属蛋白酶活性相关的病症的宿主施用一种具有出色的抑制一种或多种基质金属蛋白酶（MMP）酶活性的芳香磺酰羟肟酸有效量，例如MMP-2、MMP-9和MMP-13，同时在至少MMP-1方面表现出显著较少的抑制作用。所施用的酶抑制剂在结构上对应于下式（I）或其药学上可接受的盐，其中R1和R2均为氢基或R1和R2与它们键合的原子形成一个5到8个成员环，该环中含有一个、两个或三个杂原子，该杂原子为氧、硫或氮。式（I）中的R3为可选的取代芳基或可选的取代杂芳基基团。本发明还揭示了具有这些选择性活性的金属蛋白酶抑制剂化合物，制造这种化合物的过程以及使用抑制剂的制药组合物。